Trial Profile
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Melphalan (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 16 Oct 2020 Status changed from active, no longer recruiting to discontinued.
- 03 Oct 2017 Planned End Date changed from 31 Jul 2021 to 14 Oct 2020.
- 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.